Virus-Like Particles in Vaccine and Cancer Immunotherapy
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 304
Special Issue Editor
2. Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA
Interests: HIV vaccines; pancreatic cancer pathogenesis and therapy; nanoparticle targeted delivery; virus-like particles; cancer immunotherapy; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colloquies,
Virus-like particles (VLPs) are replication-incompetent vaccines that represent an intact, non-replicative virion lacking a genome but maintaining the original antigenic composition of the surface proteins incorporated into the virion’s outer membrane. VLPs have unique properties as particulate immunogens due to their size and pseudoviral structure, which may correctly present linear and conformational epitopes to the immune system to elicit both humoral and cellular immune responses. Therefore, it is an attractive approach and has been widely used for infectious disease vaccines and for cancer immunotherapies.
This Special Issue focuses on “Virus-like Particles in Vaccine and Cancer Immunotherapy”. Submissions of original articles, systematic reviews, short communications, and other types of articles on related topics are welcome. All manuscripts will follow standard journal peer-review practices, and those accepted for publication will appear in the issue “Virus-like Particles in Vaccine and Cancer Immunotherapy”. We look forward to receiving your contributions to the Special Issue.
Prof. Dr. Qizhi Cathy Yao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
